Genomics Industry Tries New Strategies to Engage Community Oncologists
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
Brain Cancer News
BRAIN CANCER ADVISOR
Brain Cancer News
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Short Treatment Delays May Not Hamper Survival in Glioblastoma
For patients with glioblastoma, short delays in the initiation of chemoradiotherapy after surgery were not linked to worse survival — yet initiation too soon was.
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Fewer Children Enrolling in Pediatric Cancer Trials
Adolescent and young adult cancer patients underrepresented in clinical trials.
Pediatric Brain Cancer Outcomes Worse for Black, Hispanic Patients
Disparities for disease severity not seen at diagnosis, meaning postdiagnosis factors may affect outcome.
Pedmark Receives Priority Review for Prevention of Cisplatin-Induced Ototoxicity
The application is supported by data from 2 pivotal open-label, randomized phase 3 trials (SIOPEL 6 and ACCL0431), which compared the efficacy of sodium thiosulfate plus cisplatin to cisplatin alone for the prevention of cisplatin-induced hearing loss.
Time to Radiotherapy After Glioblastoma Resection Affects Survival Outcomes
A large retrospective analysis demonstrated that a delay of 4 to 8 weeks for adjuvant radiotherapy following surgical resection of glioblastoma improved survival.
Not Developing Any New Drugs Could Be EQRx’s Biggest Innovation
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
“Medical Distancing” May Help Protect Cancer Patients From Exposure to COVID-19
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
Federal Ruling Puts Pressure on Clinical Trial Sponsors to Post Data
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
Peptide Derived From Scorpion Venom Helps CAR-T Cells Kill Gliomas in Preclinical Tests
Researchers have engineered CAR-T cells to express a peptide from scorpion venom to help them home to glioma cells.
First Human Clinical Trial in US to Test the Use of CRISPR-Modified T Cells in Cancer Answers Vital Questions
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
Improving Cancer Pain Management Amid the Opioid Crisis
Research into opioid alternatives for cancer-related pain has stalled, however substance use disorders remain problematic.
A New Trend in Drug Development: Leveraging Data from Expanded Access
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
Evidence Suggests B Cells Play a Role in Immunotherapy Response
New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.
Harnessing Key Elements of the Ebola Virus in Animal Models of Glioblastoma
A glycoprotein in Ebola called the mucin-like domain may be of interest in the development of an oncolytic for brain cancer.
The Questionable Practice That Permeates Oncology Clinical Trials
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Maximal Resection of Glioblastomas May Up Survival
Maximal resection of contrast-enhanced tumor linked to increased overall survival across all subgroups.
Integrative Oncology: Using Evidence-Informed Medicine to Improve Patient Outcomes and Quality of Life
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
Want to read more?
Please login or register first to view this content.
